Boudicca Dx, LLC
Reliable, Secure & Trusted Professional Consulting Firm
Boudicca Dx is a limited liability company incorporated in Tennessee & located 20 minutes from downtown Nashville, the “Health Care City.”
Member of the Williamson County Chamber of Commerce
Headquarters:
870 Nialta Lane
Brentwood, TN 37027-8232
For inquiries, contact: carlos@boudiccadx.com or (520) 289-6147
Business continuity tools to ensure client projects are never interrupted:
- Headquarters is powered by an emergency commercial backup generator with automatic transfer switches to smoothly switch from grid power to generator power during outages, ensuring uninterrupted operation if there is a local power outage.
- Dropbox is used to securely store client information and provide off-site data backups via cloud storage and automatically syncing of files and documents. All Boudicca Dx consultants assigned to client projects are required to work on client documents within this secure Dropbox.
- Extended version history enables recovery of files on Dropbox for up to 10 years
- Boudicca Dx interactively works with clients and external strategic alliance partners through this secure Dropbox if they do not have their own secure system
- All Boudicca Dx consultants & employees are required to utilize their Boudicca Dx managed e-mail accounts through Google Workspace to protect all confidential communications
- All Boudicca Dx global regulatory submission correspondences are separately managed through a hosted secure dedicated Microsoft Exchange e-mail server that uses a perpetual e-mail domain to further protect client’s regulatory intelligence
- Boudicca Dx has general and professional liability insurance policies through Hiscox
- All agreements are reviewed by Boudicca Dx’s appointed locally-based lawyer
Upcoming Conferences
American Pathology Foundation (APF) National Meeting
September 20-21, 2024, East Rutherford, NJ
Invited Speaker:
Kelly Gordon, PhD, MB(ASCP)CM
“Navigating the Final FDA Rule on Laboratory Developed Tests Regulated as Medical Devices”
- Summarize Technical & Regulatory requirements for each phaseout step
- Review the parallel FDA IVD Reclassification Process
- Discuss Biopharma Clinical Trial Testing & Companion Diagnostic Opportunities for Laboratories
EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
October 23-25, 2024, Barcelona, Spain
Abstract Author:
Kelly Gordon, PhD, MB(ASCP)CM
“Evaluating the Use of Merlin-YAP Dual-label Immunohistochemistry for Predicting Response to TEAD Inhibitor VT3989” with Client: Vivace Therapeutics.